Literature DB >> 8943476

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure.

N D Vaziri1, K Liang.   

Abstract

Chronic renal failure (CRF) is associated with hypertriglyceridemia, impaired clearance of very low density lipoproteins (VLDL) and chylomicrons and their remnants as well as triglyceride-enrichment of various lipoproteins. These abnormalities are indicative of depressed lipoprotein lipase (LPL)-mediated hydrolysis of triglycerides in VLD and chylomicrons. In fact, impaired post-heparin lipolytic activity and decreased adipose tissue LPL activity has been previously demonstrated in CRF. The reduction in LPL activity in CRF has been attributed to PTH-induced insulin resistance and the presence of excess lipase inhibitors in uremic plasma. However, the effect of CRF on gene expression of LPL has not been elucidated and was studied here. Heparin-releasable, detergent-extractable and total LPL activities, as well as LPL mRNA of the heart, soleus muscle and fat body were determined in male Sprague-Dawley rats at baseline and on weeks 1, 3 and 6 following 5/6 nephrectomy (CRF group) or sham operation (control group). The CRF group exhibited a marked and steady rise in plasma triglycerides along with a steady decline in LPL activities and mRNA levels of all tissues studied. In contrast, the study parameters remained virtually unchanged throughout the study period in the control group. A strong inverse correlation was found between plasma triglycerides and LPL activity in the study animals. LPL activity was directly related to LPL mRNA. We conclude that CRF results in marked down-regulation of LPL expression that can contribute to dyslipidemia and altered energy metabolism in uremia. The effect of depressed LPL expression is compounded by the previously demonstrated elevations in uremic plasma of Apo C-III and pre-beta-HDL, which are potent inhibitors of LPL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943476     DOI: 10.1038/ki.1996.515

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  32 in total

1.  Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Authors:  Nosratola D Vaziri; Kaveh Navab; Pavan Gollapudi; Hamid Moradi; Madeleine V Pahl; Cyril H Barton; Alan M Fogelman; Mohamad Navab
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

2.  Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.

Authors:  Nosratola D Vaziri; Jun Yuan; Zhenmin Ni; Susanne B Nicholas; Keith C Norris
Journal:  Clin Exp Nephrol       Date:  2011-10-19       Impact factor: 2.801

Review 3.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Clin Exp Nephrol       Date:  2013-08-24       Impact factor: 2.801

4.  Impaired postprandial lipemic response in chronic kidney disease.

Authors:  Jeffrey M Saland; Lisa M Satlin; Jeanna Zalsos-Johnson; Serge Cremers; Henry N Ginsberg
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

Review 5.  Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Authors:  Roberto Scarpioni; Marco Ricardi; Vittorio Albertazzi; Luigi Melfa
Journal:  World J Nephrol       Date:  2012-12-06

6.  Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury.

Authors:  Shenyang Li; Kiran Nagothu; Gouri Ranganathan; Syed M Ali; Brian Shank; Neriman Gokden; Srinivas Ayyadevara; Judit Megyesi; Gunilla Olivecrona; Sumant S Chugh; Sander Kersten; Didier Portilla
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-23

Review 7.  Lipoprotein metabolism and CKD: overview.

Authors:  Philip Barter
Journal:  Clin Exp Nephrol       Date:  2013-09-20       Impact factor: 2.801

Review 8.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

9.  White adipose tissue overproduces the lipid-mobilizing factor zinc α2-glycoprotein in chronic kidney disease.

Authors:  Caroline C Pelletier; Laetitia Koppe; Marine L Croze; Emilie Kalbacher; Roxane E Vella; Fitsum Guebre-Egziabher; Alain Géloën; Lionel Badet; Denis Fouque; Christophe O Soulage
Journal:  Kidney Int       Date:  2013-02-20       Impact factor: 10.612

10.  Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.

Authors:  Kyubok Jin; Keith Norris; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.